Literature DB >> 4048394

Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation.

H D Suit, R S Sedlacek, G Silver, D Dosoretz.   

Abstract

Studies of the effect of pentobarbital anesthesia on the radiation response have been performed using early generation isotransplants of three spontaneous tumors of the C3H mouse: a mammary carcinoma (MCaIV), a fibrosarcoma (FSaII), and a squamous cell carcinoma (SCCVII). The enhancement ratio of pentobarbital [ER(PB)] for TCD50 as the end point was greater than or equal to 1 for all conditions tested. The ER(PB) for O2 3 ATA conditions and two equal doses was 1.46, 1.72, and 2.21 for MCaIV, FSaII, and SCCVII, respectively. The ER(PB) using MCaIV was the same for O2 and carbogen at 1 or 3 ATA. Also, tumor size of MCaIV did not significantly affect the ER(PB) for O2 3 ATA conditions. Further, with the two-dose protocol the anesthesia and the hyperbaric oxygen needed to be used at the second dose; condition at the first dose was not critical. For fractionated irradiation of MCaIV (10 and 15 equal doses) the ER(PB) was smaller than for two-dose treatment; also the effect was less for intratumor temperature of 35 degrees C than 26-27 degrees C. There was no effect of the anesthesia on the acute response of normal skin of the leg. Lung damage by hyperbaric oxygen was not an important factor in these results. Additionally, ERs were computed for O2 at 3 ATA. This ER(O2 3 ATA) was larger for anesthesized than conscious mice. The ER(O2 3 ATA) for MCaIV was high (greater than 1.5) even for radiation given in 10 or 15 equal doses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4048394

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  16 in total

1.  In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer.

Authors:  Gal Shafirstein; Emily Oakley; Sasheen Hamilton; Michael Habitzruther; Sarah Chamberlain; Sandra Sexton; Leslie Curtin; David A Bellnier
Journal:  Methods Mol Biol       Date:  2022

2.  Controlling Immunoregulatory Cell Activity for Effective Photodynamic Therapy of Cancer.

Authors:  Mladen Korbelik; Zdzislaw M Szulc; Alicja Bielawska; Duska Separovic
Journal:  Methods Mol Biol       Date:  2022

3.  Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer.

Authors:  M Korbelik; V R Naraparaju; N Yamamoto
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Authors:  Bridget F Koontz; Frank Verhaegen; Dirk De Ruysscher
Journal:  Br J Radiol       Date:  2016-09-26       Impact factor: 3.039

5.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 6.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

7.  Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.

Authors:  B A Teicher; T S Herman; R E Hopkins; K Menon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy.

Authors:  M Korbelik; V R Naraparaju; N Yamamoto
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

9.  Growth and radiation sensitivity of the MLS human ovarian carcinoma cell line grown as multicellular spheroids and xenografted tumours.

Authors:  E K Rofstad; R M Sutherland
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

10.  Photofrin accumulation in malignant and host cell populations of various tumours.

Authors:  M Korbelik; G Krosl
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.